EMA Offers Early Access To Pfizer's COVID-19 Pill Paxlovid

by Vandana Singh, Benzinga Editor

December 16, 2021 1:23 PM | 1 min read | Make a Comment

The EMA said that European countries can begin to use Pfizer Inc's PFE COVID-19 treatment pill Paxlovid, even though it is not yet authorized in the EU.
The pill is indicated to treat adults with COVID-19 who do not require supplemental oxygen and are at increased risk of progressing to severe disease.
Related Link: Final Data Reaffirms Efficacy Of Pfizer's COVID-19 Antiviral Treatment
The early advice is based on clinical trial data from Pfizer showing 1% of patients (6 out of 607) who took Paxlovid within five days of the start of symptoms were hospitalized within 28 days of starting treatment compared with 6.7% of patients (41 out of 612) given a placebo.
The FDA has yet to authorize Pfizer's pill.
Price Action: PFE shares are up 3.71% at $61 during the market session on the last check Thursday.

Posted In: Biotech News Health Care Movers Trading Ideas General Briefs COVID-19 Coronavirus

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.